Clinical TrialMay 30, 2026, 08:02 AM
Molecular Partners to Present MP0712 Phase 1/2a Data at ASCO, SNMMI
AI Summary
Molecular Partners AG announced it will present trial-in-progress poster presentations for its lead targeted alpha radiotherapy candidate, MP0712, at the 2026 American Society of Clinical Oncology (ASCO) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meetings. MP0712 is a 212Pb-based Radio-DARPin Therapy targeting the tumor-associated protein DLL3 for small cell lung cancer and other neuroendocrine cancers. The US multicenter Phase 1/2a study (NCT07278479) is actively recruiting patients, with initial clinical data expected in 2026. Previous imaging and dosimetry data presented in January 2026 showed specific tumor uptake, supporting the clinical development plans.
Key Highlights
- MP0712 Phase 1/2a study poster presentations at ASCO (May 29-June 2) and SNMMI (May 30-June 2).
- MP0712 is a 212Pb-based Radio-DARPin Therapy targeting DLL3 for SCLC and neuroendocrine cancers.
- DLL3 is expressed in over 85% of SCLC tumors.
- The US multicenter Phase 1/2a study (NCT07278479) is actively recruiting patients.
- Initial clinical data from the study is expected in 2026.
- Previous data from January 2026 showed specific tumor uptake with 203Pb-MP0712.
Price Impact
More from MOLN